Meta-Analysis of Head-to-Head Clinical trials Comparing Incretin-Based Glucose-Lowering Medications and Basal Insulin - An Update Including Recently Developed GLP-1 Receptor Agonists and the GIP/GLP-1 Receptor Co-Agonist Tirzepatide.

In particular, recently introduced, highly effective IBGLM were superior over basal insulin treatment, reinforcing the recommendation that IBGLM should be considered as the first injectable treatment for most patients with type 2 diabetes. This article is protected by copyright. All rights reserved.